Drugs that inhibit complement

Transfusion and Apheresis Science

Volumn 46, Issue 1, 2012, Pages 87-92

  Schrezenmeier, Hubert ^a   Höchsmann, Britta ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; ARGININE; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; ECULIZUMAB; HEMOGLOBIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E7; ORNITHINE; TT 30; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ALLERGIC ASTHMA; ANCA ASSOCIATED VASCULITIS; ARTHRITIS; BONE MARROW DEPRESSION; C3 NEPHROPATHY; COLD AGGLUTININ DISEASE; COMPLEMENT INHIBITION; DERMATOMYOSITIS; DYSPNEA; ERYTHROCYTE; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; INTRAVASCULAR HEMOLYSIS; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LONG TERM SURVIVAL; MOTOR NEURON DISEASE; MYASTHENIA GRAVIS; OFF LABEL DRUG USE; PANCREAS TRANSPLANTATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN DEFECT; PULMONARY HYPERTENSION; QUALITY OF LIFE; RETINA MACULA DEGENERATION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOPHILIA;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; COMPLEMENT INACTIVATING AGENTS; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYTIC-UREMIC SYNDROME; HUMANS;

EID: 84857453050     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2011.11.012     Document Type: Review

References (58)

1. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25(11):1256-1264.
2. Thomas T.C., Rollins S.A., Rother R.P., Giannoni M.A., Hartman S.L., Elliott E.A., et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996, 33(17-18):1389-1401.
3. Luzzatto L. Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-cell mosaicism. Curr Opin Genet Dev 2006, 16(3):317-322.
4. Hernandez-Campo P.M., Almeida J., Acevedo M.J., Sanchez M.L., Alberca I., Vidriales B., et al. Detailed immunophenotypic characterization of different major and minor subsets of peripheral blood cells in patients with paroxysmal nocturnal hemoglobinuria. Transfusion 2008, 48(7):1403-1414.
5. Richards S.J., Hillmen P. Immunophenotypic analysis of PNH cells. Curr Protoc Cytom 2002, 12. [chapter 6:Unit].
6. Nebe T., Schubert J., Gutensohn K., Schrezenmeier H. Flow cytometric analysis of GPI-deficient cells for the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). J Lab Med 2003, 27:257-265.
7. Hillmen P., Lewis S.M., Bessler M., Luzzatto L., Dacie J.V. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995, 333(19):1253-1258.
8. de Latour R.P., Mary J.Y., Salanoubat C., Terriou L., Etienne G., Mohty M., et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008, 112(8):3099-3106.
9. Socie G., Mary J.Y., De Gramont A., Rio B., Leporrier M., Rose C., et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology [see comments]. Lancet 1996, 348(9027):573-577.
10. Brodsky R.A., Young N.S., Antonioli E., Risitano A.M., Schrezenmeier H., Schubert J., et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008, 111(4):1840-1847.
11. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socie G., Muus P., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355(12):1233-1243.
12. Hillmen P., Muus P., Dührsen U., Risitano A.M., Schubert J., Luzzatto L., et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood 2007, 110(12):4123-4128.
13. Schubert J., Hillmen P., Röth A., Young N.S., Elebute M.O., Szer J., et al. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2008, 142(2):263-272.
14. Hill A., Hillmen P., Richards S.J., Elebute D., Marsh J.C., Chan J., et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005, 106(7):2559-2565.
15. Höchsmann B, Leichtle R, von Zabern I, Kaiser S, Flegel W, Schrezenmeier H. Paroxysmal nocturnal hemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test. Vox Sang; 2011. [Epub ahead of print].
16. Hill A., Rother R.P., Arnold L., Kelly R., Cullen M.J., Richards S.J., et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010, 95(4):567-573.
17. Risitano A.M., Notaro R., Marando L., Serio B., Ranaldi D., Seneca E., et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009, 113(17):4094-4100.
18. Luzzatto L., Risitano A.M., Notaro R. Paroxysmal nocturnal hemoglobinuria and eculizumab. Haematologica 2010, 95(4):523-526.
19. Risitano A.M., Notaro R., Luzzatto L., Hill A., Kelly R., Hillmen P. Paroxysmal nocturnal hemoglobinuria - hemolysis before and after eculizumab. N Engl J Med 2010, 363(23):2270-2272.
20. Kristiansen M., Graversen J.H., Jacobsen C., Sonne O., Hoffman H.J., Law S.K., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409(6817):198-201.
21. Olson J.S., Foley E.W., Rogge C., Tsai A.L., Doyle M.P., Lemon D.D. NO scavenging and the hypertensive effect of hemoglobin-based blood substitutes. Free Radic Biol Med 2004, 36(6):685-697.
22. Schnog J.J., Jager E.H., van der Dijs F.P., Duits A.J., Moshage H., Muskiet F.D., et al. Evidence for a metabolic shift of arginine metabolism in sickle cell disease. Ann Hematol 2004, 83(6):371-375.
23. Hill A., Rother R.P., Wang X., Morris S.M., Quinn-Senger K., Kelly R., et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2010, 149(3):414-425.
24. Rother R.P., Bell L., Hillmen P., Gladwin M.T. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005, 293(13):1653-1662.
25. Olsen S.B., Tang D.B., Jackson M.R., Gomez E.R., Ayala B., Alving B.M. Enhancement of platelet deposition by cross-linked hemoglobin in a rat carotid endarterectomy model. Circulation 1996, 93(2):327-332.
26. Studt J.D., Hovinga J.A., Furlan M., Lammle B. Discrepant activity levels of von Willebrand factor-cleaving protease (ADAMTS-13) in congenital thrombotic thrombocytopenic purpura. Blood 2003, 102(3):1148.
27. Schafer A., Wiesmann F., Neubauer S., Eigenthaler M., Bauersachs J., Channon K.M. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 2004, 109(15):1819-1822.
28. Matejovic M., Krouzecky A., Radej J., Rokyta R., Kralova H., Radermacher P., et al. Coagulation and endothelial dysfunction during longterm hyperdynamic porcine bacteremia - effects of selective inducible nitric oxide synthase inhibition. Thromb Haemost 2007, 97(2):304-309.
29. Gralnick H.R., Vail M., McKeown L.P., Merryman P., Wilson O., Chu I., et al. Activated platelets in paroxysmal nocturnal haemoglobinuria. Br J Haematol 1995, 91(3):697-702.
30. Wiedmer T., Hall S.E., Ortel T.L., Kane W.H., Rosse W.F., Sims P.J. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood 1993, 82:1192-1196.
31. Hugel B., Socie G., Vu T., Toti F., Gluckman E., Freyssinet J.M., et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood 1999, 93(10):3451-3456.
32. Ploug M., Plesner T., Ronne E., Ellis V., Hoyer Hansen G., Hansen N.E., et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood 1992, 79:1447-1455.
33. Helley D., de Latour R.P., Porcher R., Rodrigues C.A., Galy-Fauroux I., Matheron J., et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010, 95(4):574-581.
34. Grunewald M., Siegemund A., Grunewald A., Schmid A., Koksch M., Schopflin C., et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis 2003, 14(7):685-695.
35. Kelly R.J., Hill A., Arnold L.M., Brooksbank G.L., Richards S.J., Cullen M., et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood 2011, 117(25):6786-6792.
36. Hall C., Richards S., Hillmen P. Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH). Blood 2003, 102(10):3587-3591.
37. Hillmen P., Elebute M., Kelly R., Urbano-Ispizua A., Hill A., Rother R.P., et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol 2010, 85(8):553-559.
38. Nishimura J., Kanakura Y., Ware R.E., Shichishima T., Nakakuma H., Ninomiya H., et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) 2004, 83(3):193-207.
39. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361(17):1676-1687.
40. Nurnberger J., Philipp T., Witzke O., Opazo S.A., Vester U., Baba H.A., et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360(5):542-544.
41. Kose O., Zimmerhackl L.B., Jungraithmayr T., Mache C., Nurnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010, 36(6):669-672.
42. Legendre C, Babu S, Furman R, et al. Safety and efficacy of eculizumab in aHUS patients resistant to plasma therapy: interim analysis from a Phase II trial. In: Abstract presented at the 43rd annual meeting of the American Society of Nephrology, Denver, CO, November 16-21, 2010. Available from: http://wwwabstracts2viewcom/asn/viewphp?nu=ASN10L1_1338a&terms2011.
43. Muus P, Legendre C, Douglas K, et al. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis from a Phase II trial. In: Abstract presented at the 43rd annual meeting of the American Society of Nephrology, Denver, CO, November 16-21, 2010. Available from: http://wwwabstracts2viewcom/asn/viewphp?nu=ASN10L1_157a&terms2011.
44. Lapeyraque A.L., Fremeaux-Bacchi V., Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011, 26(4):621-624.
45. Kupferschmidt K. Infectious diseases. As E. coli outbreak recedes, new questions come to the fore. Science 2011, 333(6038):27.
46. Biglarnia A.R., Nilsson B., Nilsson T., von Zur-Muhlen B., Wagner M., Berne C., et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011, 24(8):e61-e66.
47. Chandran S., Baxter-Lowe L., Olson J.L., Tomlanovich S.J., Webber A. Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation - a case report. Transplant Proc 2011, 43(5):2097-2101.
48. Roth A., Huttmann A., Rother R.P., Duhrsen U., Philipp T. Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood 2009, 113(16):3885-3886.
49. Roth A., Duhrsen U. Cold agglutinin disease. Eur J Haematol 2010, 84(1):91.
50. Bommer M., Höchsmann B., Flegel W., Döhner H., Schrezenmeier H. Successful treatment of complement mediated refractory hemolysis associated with cold and warm autoantibodies using eculizumab. Haematologica 2011, 94(Suppl. 2):241. [abs. 0593].
51. Fitzpatrick A.M., Mann C.A., Barry S., Brennan K., Overell J.R., Willison H.J. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 2011, 16(2):84-91.
52. Ehrnthaller C., Ignatius A., Gebhard F., Huber-Lang M. New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 2011, 17(3-4):317-329.
53. Hill A., Ridley S.H., Esser D., Oldroyd R.G., Cullen M.J., Kareclas P., et al. Protection of erythrocytes from human complement-mediated lysis by membrane-targeted recombinant soluble CD59: a new approach to PNH therapy. Blood 2006, 107(5):2131-2137.
54. Banda N.K., Levitt B., Glogowska M.J., Thurman J.M., Takahashi K., Stahl G.L., et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 2009, 183(9):5928-5937.
55. Atkinson C., Song H., Lu B., Qiao F., Burns T.A., Holers V.M., et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005, 115(9):2444-2453.
56. Song H., Qiao F., Atkinson C., Holers V.M., Tomlinson S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol 2007, 179(11):7860-7867.
57. Lindorfer M.A., Pawluczkowycz A.W., Peek E.M., Hickman K., Taylor R.P., Parker C.J. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement. Blood 2010, 115(11):2283-2291.
58. Emlen W., Li W., Kirschfink M. Therapeutic complement inhibition: new developments. Semin Thromb Hemost 2010, 36(6):660-668.